Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

1.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
[PubMed - indexed for MEDLINE]
2.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.

Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

Am J Clin Dermatol. 2011 Feb 1;12(1):51-62. doi: 10.2165/11530640-000000000-00000.

PMID:
21110526
[PubMed - indexed for MEDLINE]
3.

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.

Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.

Br J Dermatol. 2008 Mar;158(3):549-57. Epub 2007 Nov 28.

PMID:
18047521
[PubMed - indexed for MEDLINE]
4.

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.

J Dermatolog Treat. 2007;18(1):25-31.

PMID:
17365264
[PubMed - indexed for MEDLINE]
5.

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.

Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.

Health Qual Life Outcomes. 2008 Oct 2;6:75. doi: 10.1186/1477-7525-6-75.

PMID:
18831744
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
[PubMed - indexed for MEDLINE]
7.

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

Health Qual Life Outcomes. 2006 Sep 27;4:71.

PMID:
17005043
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.

Maksymowych WP, Gooch KL, Wong RL, Kupper H, van der Heijde D.

J Rheumatol. 2010 Feb;37(2):385-92. doi: 10.3899/jrheum.090242. Epub 2009 Dec 1.

PMID:
19955052
[PubMed - indexed for MEDLINE]
9.

Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr.

J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38.

PMID:
14964744
[PubMed - indexed for MEDLINE]
10.

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

Clin Drug Investig. 2011;31(1):51-60. doi: 10.2165/11539360-000000000-00000.

PMID:
20932070
[PubMed - indexed for MEDLINE]
11.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

J Am Acad Dermatol. 2012 Feb;66(2):e67-76. doi: 10.1016/j.jaad.2010.10.020. Epub 2011 May 25.

PMID:
21616560
[PubMed - indexed for MEDLINE]
12.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.

Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.

Br J Dermatol. 2012 Dec;167(6):1374-81. doi: 10.1111/bjd.12000. Epub 2012 Nov 2.

PMID:
22897348
[PubMed - indexed for MEDLINE]
13.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x. Epub 2008 Oct 3. Erratum in: Am J Gastroenterol. 2009 Jul;104(7):1894.

PMID:
18853973
[PubMed - indexed for MEDLINE]
14.

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J.

Ann Rheum Dis. 2007 Feb;66(2):163-8. Epub 2006 Oct 17.

PMID:
17046964
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.

Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9.

PMID:
19903183
[PubMed - indexed for MEDLINE]
16.
17.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.

Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20.

PMID:
21173304
[PubMed - indexed for MEDLINE]
18.

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.

Strand V, Fiorentino D, Hu C, Day RM, Stevens RM, Papp KA.

Health Qual Life Outcomes. 2013 May 10;11:82. doi: 10.1186/1477-7525-11-82.

PMID:
23663752
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

Br J Dermatol. 2005 Dec;153(6):1192-9.

PMID:
16307657
[PubMed - indexed for MEDLINE]
20.

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.

Br J Dermatol. 2006 Jun;154(6):1161-8.

PMID:
16704649
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk